Carbapenemase‐producing Klebsiella pneumoniae: a major clinical challenge

@article{Mandrawa2016CarbapenemaseproducingKP,
  title={Carbapenemase‐producing Klebsiella pneumoniae: a major clinical challenge},
  author={Christine L Mandrawa and Katie Cronin and Kirsty L. Buising and Yves S Poy Lorenzo and Mary Jo Waters and Cameron J Jeremiah},
  journal={Medical Journal of Australia},
  year={2016},
  volume={204}
}
A 59-year-old man from rural Victoria, with no hospital contact for 15 years or recent history of international travel, presented to his local hospital with severe acute pancreatitis secondary to gallstones. He was transferred to a metropolitan hospital for further management, including intermittent admissions to the intensive care unit (ICU) for haemodynamic support. On Day 4 of admission, empirical antibiotics were prescribed for severe pancreatitis and concurrent nosocomial pneumonia… 
View on Wiley
mja.com.au
9 Citations
Background Citations
3

9 Citations

Citation Type

Citation Type

Risk factors for KPC-producing Enterobacteriaceae acquisition and infection in a healthcare setting with possible local transmission: a case-control study.
Use of Next Generation Sequencing and Synergy Susceptibility Testing in Diagnosis and Treatment of Carbapenem-Resistant Klebsiella pneumoniae Blood Stream Infection
TLDR
The identification by next generation sequencing and treatment according to synergy susceptibility testing in the case of a 29-year-old systemic lupus erythematosus female with CR-Kp blood stream infection is reported.
Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options.
TLDR
PDR GNB are increasingly being reported worldwide and are associated with high mortality, and several treatment regimens have been successfully used, of which synergistic combinations appear to be most promising and often the only available option.
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
TLDR
To the authors' knowledge, this is the first clinical study to show a benefit of combination over monotherapy with polymyxin B for severe extensively drug-resistant A. baumannii or P. aeruginosa infections.
A structural, epidemiological & genetic overview of Klebsiella pneumoniae carbapenemases (KPCs)
TLDR
Clinicians are likely to opt for unconventional combinations of antibiotics to treat KPC infections because of unavailability of alternative agents, and treatment options highlighting the drugs under development are highlighted.
The ASID test
This year, 2016, is a historic year for the Australasian Society for Infectious Diseases (ASID), being the 40th anniversary of the formation of the society. It is an opportunity not only to celebrate…
“When the Bug Cannot Be Killed”—The Rising Challenge of Antimicrobial Resistance
TLDR
Only with sustained, concerted, and coordinated global efforts are the authors likely to overcome the current and future challenges posed by these emerging “superbugs”.
Effect of refrigeration on prevalence and enumeration of psychrotrophic bacteria in raw milk
TLDR
Refrigeration exerted profound effect conferring diminished growth of Citrobacter, Enterobacter and Serratia, however, it Favoured Salmonella, E.coli and Klebsiella on other hand.
Himatanthus drasticus Leaves: Chemical Characterization and Evaluation of Their Antimicrobial, Antibiofilm, Antiproliferative Activities
TLDR
It is suggested that compounds from H. drasticus have antimicrobial and antibiofilm activities against K. pneumoniae and display low cytotoxicity and anti-proliferative action in PBMC stimulated with lipopolysaccharide.

References

SHOWING 1-10 OF 11 REFERENCES
Managing a nosocomial outbreak of carbapenem‐resistant Klebsiella pneumoniae: an early Australian hospital experience
TLDR
An outbreak of KPC‐2 producing K. pneumoniae at an Australian hospital is described and described as the first report of its kind in Australasia to date.
The growing burden of multidrug‐resistant infections among returned Australian travellers
A previously well 66‐year‐old man was repatriated from Athens, Greece, to the Austin Hospital for ongoing management after a protracted hospital admission for an ischiorectal abscess secondary to…
Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae
TLDR
Ertapenem plus doripenem or meropenem were given in three patients suffering from pandrug-resistant, KPC-2-positive Klebsiella pneumoniae bacteremia and urinary tract infection, and all responded successfully, without relapse at follow-up.
Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
TLDR
The use of combination therapy for definitive therapy appears to be associated with improved survival in bacteremia due to KPC-producing K. pneumoniae.
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.
  • M. Tumbarello, P. Viale, +11 authors M. Bassetti
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
To improve survival, combined treatment with 2 or more drugs with in vitro activity against the isolate, especially those also including a carbapenem, may be more effective than active monotherapy.
Prevalence and Risk Factors for Acquisition of Carbapenem-Resistant Enterobacteriaceae in the Setting of Endemicity
TLDR
Critical illness and underlying medical conditions, CRE colonization pressure, and antimicrobial exposure are important risk factors for CRE acquisition, and adherence to infection control practices and antimacterial stewardship appear to be critical components of a CRE control program.
Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections.
Herein, we evaluated through antibiotic kill studies the in vitrosynergistic activity of meropenem plus ertapenem againstpandrug-resistant CP-Kp isolated from three patients with bacter-aemia who…
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
TLDR
Ceftazidime/avibactam plus metronidazole was effective and generally well tolerated in patients with cIAI, with a favourable clinical response rate in the ME population of >90%, similar to that of meropenem.
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
TLDR
NXL104 inhibitory activity is unique in terms of spectrum, encompassing class A extended-spectrum β-lactamases, class C enzymes and class A carbapenemases, and given the limited therapeutic options available for infections caused by multiresistant Enterobacteriaceae isolates, it is a promising agent to be used in combination with a β- lactam to protect its antibacterial activity.
Characterization of the blaKPC-2 and blaKPC-3 genes and the novel blaKPC-15 gene in Klebsiella pneumoniae.
TLDR
The study concluded that carbapenem resistance in the three isolates was primarily due to the production of carbAPenem-hydrolysing β-lactamase.
...
1
2
...